
Stevanato Group
INNOVATION
ROADSHOW
September 23, 2025
Boston, MA, U.S.

Stevanato Group

INNOVATION ROADSHOW

September 23, 2025
Boston, MA, U.S.

CONTENTS

Stevanato Group

INNOVATION ROADSHOW

September 23, 2025
Boston, MA, U.S.

CONFERENCE AGENDA

Morning session:
Drug Product Injectability and Interaction

9:00-9:45	**Registrations**
9:45-9:55	**Welcome and Introduction of Stevanato Group** Lisa Miles, Stevanato Group
9:55-10:10	**Navigating The Future Of Pharma: Outlook And Major Trends In The End-Market And Primary Packaging** Luke Greenwalt, IQVIA
10:10-10:30	**De-Risking Combination Product Development: Integration of Aidaptus® Autoinjector with High-Performance Alba® Prefillable Syringe** Terence O'Hagan & Enrico Barichello, Stevanato Group
10:30-10:50	**From Intravenous to Subcutaneous Administration: Vertiva® 10ml, Large-Volume Glass Cartridges** Terence O'Hagan & Alan Xu, Stevanato Group
10:50-11:05	**Enabling LNP Drug Delivery: Prefilled Syringe Head-to-Head Study** Odra Pinato, Stevanato Group
11:05-11:20	**Coffee break**
11:20-11:40	**Enhancing Efficiency and Value with RTU and RTS Components: Unlocking Synergistic Opportunities** Yusuf Oni, Bristol-Myers Squib
11:40-11:55	**Case Study: Long-Term Placebo Stability with Polysorbate 80 in Silicone-Oil Glass PFS and Risk Mitigation Strategies** Enrico Barichello, Stevanato Group
11:55-12:15	**Evaluating Innovative Primary Packaging Solutions: A CDMO Perspective on the Alba® Syringe** Caroline Peskoller, Vetter
12:15-13:45	**Lunch**
13:30-14:00	**Registrations**

Stevanato Group

INNOVATION ROADSHOW

September 23, 2025
Boston, MA, U.S.

CONFERENCE AGENDA

Afternoon session:
Fill & Finish and
Supply Chain Performances

14:00-14:10	**Welcome and Introduction of Stevanato Group** Lisa Miles, Stevanato Group
14:10-14:25	**Navigating The Future Of Pharma: Outlook And Major Trends In The End-Market And Primary Packaging** Luke Greenwalt, IQVIA
14:25-14:40	**Fill & Finish Operations: Achieve Higher Productivity and Lower Risks of Breakages for the Final Patient with Nexa® Vials** Alan Xu, Stevanato Group
14:40-15:00	**Accelerating Small Batch Inspection: A Real-World Case Study Combining AI and Advanced Technology by Stevanato Group and Roche** Federico Scattolin, Stevanato Group
15:00-15:20	**Performance of Visual Inspection: Challenges and Innovations (AI and Digital Twin)** Federico Scattolin, Stevanato Group
15:20-15:40	**Impact of Digitalization for Discrete Manufacturing in Pharma - Lead Time and Product Novelty** Otto Abildgaard, Stevanato Group
15:40-15:55	**Coffee break**
15:55-16:00	**Presenting Our Excellence Hub in the US**
16:00-16:15	**Ready-to-Use Packaging Benefits & Cost Savings** Dhaval Patel, INCOG BioPharma Services
16:15-16:35	**Innovation and Sustainability: A Success Story in the Stevanato Group Supply Chain** Pietro Negri & Claudio Venosta, Asset
16:35-16:38	**Conclusions** Lisa Miles, Stevanato Group
16:38-18:00	**Networking Reception**

Conference Presenter

LISA MILES

CCIO (Chief Communications and Investor Relations Officer),
Stevanato Group

With more than 25 years of experience, Lisa Miles joined Stevanato Group in 2021 as Senior Vice President of Investor Relations and then assumed the role of Chief Communications and Investor Relations Officer in 2024. Lisa currently is responsible for the Group's global communications, media, and brand strategy, as well as the investor relations function.
Previously, Lisa spent 18 years at Maximus in various management positions. In her most recent role, she served as Senior Vice President of Investor Relations & Corporate Communications for nearly a decade where she was responsible for investor relations, global marketing and branding, media relations, and employee communications.
Named to the 2017 and 2018 Institutional Investor's All America Executive Team for Midcap Investor Relations, Lisa was ranked third for Best Midcap IR Professionals in the Business, Education, and Professional Services sector. She holds a bachelor's degree in communications from The Pennsylvania State University and successfully completed an executive leadership program in management and negotiation at the Harvard Business School.

LUKE GREENWALT

Vice President and Lead, IQVIA Center for US Thought Leadership, IQVIA

With a distinguished career spanning a quarter of a century in the life sciences sector, Luke Greenwalt has cultivated a reputation for strategic vision and operational excellence. Renowned for his analytical acumen and collaborative spirit, Luke has played a pivotal role in shaping thought leadership within the pharmaceutical and healthcare landscapes.
Luke has firsthand experience launching brands, managing product portfolios, and addressing real world challenges manufacturer's face as they commercialize assets. He has worked across hundreds of clients and is a recognized industry thought leader with focuses on macroeconomic industry trends, pricing and value, launch excellence, innovative contracting and payer controls, patient affordability and copay programs, and gross to net strategies amongst other areas. Luke is an originator and collaborator on over two dozen white papers and frequent speaker on contemporary topics to the life science industry.
Luke holds an undergraduate degree from the University of Iowa and an MBA from St Ambrose University where he graduated summa cum laude.

NAVIGATING THE FUTURE OF PHARMA: OUTLOOK AND MAJOR TRENDS IN THE END-MARKET AND PRIMARY PACKAGING

The speech outlines key trends shaping the global biopharmaceutical landscape through 2030, with a focus on biologics and vaccines. It highlights the rapid growth of GLP-1 therapies, the resurgence of mRNA vaccines, and the evolving role (in terms of future adoption in the different Pharma segments) of Drug Containment and Delivery Systems.

TERENCE O'HAGAN

Vice President of Business Development of Drug Delivery Systems, Stevanato Group

Mr. O'Hagan joined the Stevanato Group as Vice President of Business Development of Drug Delivery Systems in January 2025. Prior to joining the Stevanato Group, he was General Manager of Haselmeier, the US entity of the Haselmeier Group based in Stuttgart, Germany (now a medmix company). Joining the company in November of 2013, Mr. O'Hagan established the US entity and grew the America region.
Mr. O'Hagan has spent the last 21 years focused on the development and manufacturing of medical devices.
He previously worked at Radius Product Development (now a Jabil Company) as the Global director of Business Development from 2003 to 2010, and as Sr. Director of Business Development at Flextronics Medical from 2010 to 2013.
Mr. O'Hagan earned a Bachelor of Science in Plastics Engineering from the University of Lowell and a Master of Business Administration from Worcester Polytechnic Institute.

DE-RISKING COMBINATION PRODUCT DEVELOPMENT: INTEGRATION OF AIDAPTUS® AUTOINJECTOR WITH HIGH-PERFORMANCE ALBA® PREFILLABLE SYRINGE *- with Enrico Barichello*

The Aidaptus autoinjector and Alba® syringe are advanced, flexible platforms designed to meet the increasing demand for subcutaneous delivery of high value injectables.
The innovative approach of a single autoinjector solution accommodating both 1mL and 2.25mL syringes provides high flexibility without requiring additional development. The expanded capability of Stevanato Group related to device and primary packaging demonstrates how a well-integrated development strategy can mitigate compatibility challenges by design.
This presentation highlights how Alba®, a high-performance syringe platform, fully meets device compatibility requirements in terms of design and critical dimensional attributes. The Alba® syringe shows a consistent break loose and glide forces along shelf life, enabling smooth and controlled drug delivery. This study includes syringes performance data, such as break loose force, glide force, alongside autoinjector performance metrics (i.e. cap removal force, dose accuracy and injection time).
Ultimately, the presentation shows how Alba® syringe mitigates silicone oil particle release, which might impact the safety and efficacy of the drug. This work highlights how the combination of Stevanato Group's high-performance PFS and the Aidaptus® autoinjector offers to pharmaceutical companies a reliable, scalable, and patient-centric drug delivery solution, supporting the accelerated development of biologics and other advanced therapies.

TERENCE O'HAGAN

Vice President of Business Development of Drug Delivery Systems,
Stevanato Group

FROM INTRAVENOUS TO SUBCUTANEOUS ADMINISTRATION: VERTIVA® 10ML, LARGE-VOLUME GLASS CARTRIDGES - *with Alan Xu*

As the pharmaceutical industry continues to shift from hospital-based intravenous (IV) therapies to patient-centric subcutaneous (SC) delivery, the demand for large-volume injection systems is rapidly increasing. This presentation explores the key market drivers behind this transition, including patient convenience, healthcare cost reduction, and the growing pipeline of biologics requiring higher dosing volumes.
This speech will introduce Vertiva®, Stevanato Group's On-Body Delivery System (OBDS), with a focus on its 10mL configuration. Attendees will gain insights into the system's core functionalities, patient-centric design, and the value it delivers to both pharmaceutical partners and end users. The session will also highlight Stevanato Group's large-volume cartridge portfolio and our capabilities to characterize and verify its integration with proprietary and third-party delivery devices— supporting a broad range of drug formulations and administration platforms.
This presentation offers a comprehensive overview of how Stevanato Group is enabling the future of large-volume SC drug delivery through innovation, collaboration, and technical excellence.

ODRA PINATO

Analytical Services Manager, Technology Excellence Center,
Stevanato Group

Odra Pinato joined Stevanato Group in 2014 as Subject Matter Expert for the characterization of drug-primary packaging interaction. Since 2016, she has been heading the EMEA Technology Excellence Center (TEC) Analytics, the Stevanato analytical laboratory operating under the R&D department aimed to the test the physico-chemical and mechanical attributes of primary packaging and drug interaction and the performances of injector system.
Odra holds a Ph.D. in Biochemistry and Biotechnology. Her academic background is mainly focused on protein biochemistry with a 2-year post-doctoral experience in nucleic acids biophysics and pharmaceutical chemistry.

ENABLING LNP DRUG DELIVERY: PREFILLED SYRINGE HEAD-TO-HEAD STUDY

Lipid nanoparticles (LNPs) encapsulate nucleic acids and are key to new biologics like mRNA vaccines. Prefilled syringes (PFS) offer better dosing and ease of use, but there's limited stability data for LNP formulations. To address this, Stevanato Group partnered with the University of Padua to evaluate PFS suitability for LNP-based drugs. The results show that our crosslinked glass and polymer syringes are a strong fit for these advanced therapies, supporting safe and efficient delivery.

YUSUF ONI

Head of Parenteral Packaging,
Bristol-Myers Squibb

Dr. Yusuf Oni is the Head of Parenteral Packaging at Bristol Myers Squibb where he is involved in all aspects of primary packaging & device development in the parenteral product development space. Prior to joining BMS, Yusuf led the design and development of material solutions for various medical products and packaging applications in the Materials Science and Technology group at BD Medical. Yusuf is also involved in academic instruction.
He currently serves as an Adjunct Faculty in the Biomedical Engineering department at New Jersey Institute of Technology. Yusuf holds a BSc degree in Chemical Engineering from New Mexico Institute of Mining and Technology and a PhD in Mechanical and Aerospace Engineering
(with a concentration in Materials Science) from Princeton University.

ENHANCING EFFICIENCY AND VALUE WITH RTU AND RTS COMPONENTS: UNLOCKING SYNERGISTIC OPPORTUNITIES

- Introduction to packaging development strategies
- Interchangeability between RTU and RTS as an important lever
- Assessments and data analysis
- Learnings and Conclusions

ENRICO BARICHELLO

Product Manager, Syringe Platform,
Stevanato Group

Enrico Barichello holds a Master's degree in Industrial Engineering from the University of Padua.
Since joining Stevanato Group in 2017, Mr. Barichello has worked closely with cross-functional teams to define and execute the roadmap for new products, including the Alba® platform.
Since 2023, he has overseen the glass syringe platform, and as of January 2025, he also manages the polymer syringe platform, driving innovation and growth across Stevanato Group's syringe portfolio.

CASE STUDY: LONG-TERM PLACEBO STABILITY WITH POLYSORBATE 80 IN SILICONE-OIL GLASS PFS AND RISK MITIGATION STRATEGIES

This case study investigates the long-term stability of prefilled glass syringes with varying siliconization levels and stopper types, evaluated in both 1 mL long and 2.25 mL formats. A placebo solution containing polysorbate 80 was used for filling. Conducted collaboratively by Coriolis Pharma and Stevanato Group over a 21-month stability period, the study assessed subvisible particles (SbVP) and key mechanical performance parameters—including Break Loose and Extrusion Forces—across both syringe formats. The results offer insights to support the selection of syringe configurations optimized for biologics, as well as risk mitigation strategies during drug development.

CAROLINE PESKOLLER

Team Lead Primary Packaging Service and Projects,
Vetter

With a PhD in Analytical Chemistry, Caroline Peskoller has been part of Vetter Pharma since 2016, where she has built deep expertise in primary packaging for injectable drug products.
Together with her team, she supports customers throughout their fill & finish projects — from early clinical development to commercial production. The team evaluates innovative packaging solutions and helps identify and select primary packaging materials that meet the specific needs of each product and phase.

EVALUATING INNOVATIVE PRIMARY PACKAGING SOLUTIONS: A CDMO PERSPECTIVE ON THE ALBA® SYRINGE

As a CDMO, we continuously assess new primary packaging solutions entering the market to support our customers in selecting materials that meet their product needs.
Our focus lies in material characterization, processability of filling lines, and the early identification of potential challenges. In this presentation, we will share insights from our recent evaluation of the plasma coated Alba® syringe. We conducted a series of pre-assessment trials to understand its performance characteristics and compatibility with our manufacturing processes.

ALAN XU

Technical Business Development, DCS and Analytical Services,
Stevanato Group

After three years as Product Manager of Analytical Services for Stevanato Group's Technology Excellence Centers (US TEC in Boston and EMEA TEC in Italy), Alan Xu is now providing a broader range of support for pharmaceutical partners as Technical Business Development for both our Drug Containment Solutions (DCS) and Analytical Services. By leveraging his background in pharmaceutical combination devices, he guides partners from their primary container strategy through its design verification. Alan previously was an Engineering Manager for a start-up autoinjector company leading the development, design transfer, and pilot production of a novel, high-performance primary container per ISO 11040. He holds a degree in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).

FILL & FINISH OPERATIONS: ACHIEVE HIGHER PRODUCTIVITY AND LOWER RISKS OF BREAKAGES FOR THE FINAL PATIENT WITH NEXA® VIALS

In the pharmaceutical industry, safety and integrity of the drug product are of the utmost importance. Moreover, control of contamination throughout the entire drug manufacturing process is crucial to guarantee product quality and safety. Especially for biologics and high value drugs, primary containers play a pivotal role in ensuring drug protection throughout their entire lifecycle, to guarantee patients' safety and maximize efficiency and financial return on investments for Pharma companies.
Nexa® vials, thanks to their improved manufacturing process, reduce the risk of container and finished product waste due to cosmetic and mechanical issues caused by the stress generated during pharma operations, leading to improved process efficiency and lower risk of drug contamination due to glass breakage.
To verify these improved performances, 2R vials in different configurations have been characterized after a simulation of a customer's fill & finish process. Mechanical resistance of the distinct categories has been analyzed at different points of F&F process to evaluate the impact of the different steps, as well as to assess any difference between the categories in mechanical performance. In addition, after the full F&F process both categories were passed through an Automatic Visual Inspection to assess the risk of rejection due to cosmetic defects.

FEDERICO SCATTOLIN

System Owner AI,
Stevanato Group

Federico holds a master's degree in software engineering. He has solid experience in the design and commissioning of measurement and inspection equipment.
Federico started his career as a software developer in 2006 in MerMec, a leading provider of inspection equipment and services solutions for railway and steel manufacturing.
He then focused on engineering, team coordination, product development and product management, covering different positions with increasing responsibilities over the years.
In early 2019, Federico joined Stevanato Group as a Senior Vision Specialist and System Owner for Artificial Intelligence. He is currently leading the department's AI team and overseeing AI-related projects.

ACCELERATING SMALL BATCH INSPECTION: A REAL-WORLD CASE STUDY COMBINING AI AND ADVANCED TECHNOLOGY BY STEVANATO GROUP AND ROCHE

Right first time and flexibility are the most challenging requirements for the inspection of parenteral drug products even more when we look to the future. Modern pharmaceutical production drives drug product portfolios in the direction of high-value drugs with low volumes and low order sizes. Inspection speed may become less important and multi-format inspection systems will reduce the time-to-market.
Stevanato Group has joined forces with F. Hoffmann-La Roche AG to deliver a process innovation driven by the development of Vision Robot Unit (VRU): capable of fully automated, flexible, multi-format inspection, integrating artificial intelligence. In this speech, we will present the outcome and results of a real visual inspection application for a small-batch biotech product of high-value. We will explain the benefits of a flexible solution ready for scale-out and a fleet approach matching the idea of the factory of the future and serving the manufacturing needs of both clinical trial and industrialization phases.

FEDERICO SCATTOLIN

System Owner AI,
Stevanato Group

PERFORMANCE OF VISUAL INSPECTION: CHALLENGES AND INNOVATIONS (AI AND DIGITAL TWIN)

- Introduction to AVI and traditional inspection, common challenges
- Artificial Intelligence: A Journey from Tradition to Innovation
- AI governance: Stevanato Group approach to model development and validation
- Successful use cases: AI applied to vision inspection
- Inspection Digital Twin

OTTO ABILDGAARD

Digitalization Manager,
Stevanato Group

Otto Abildgaard is Digitalization Manager at Stevanato Group. He gained his experience in high-technology manufacturing processes as specialist and technical project management. He specializes in combining sensor technology and data science with his passion for making digital products visible and valuable.
As Manager of Digitalization, he is responsible for improving our products related to Data Utilization and Machine Design (Digital Twin) from an organizational perspective. He focuses on shaping the content and deployment process to meet our customers' needs and help manage their complexity.

IMPACT OF DIGITALIZATION FOR DISCRETE MANUFACTURING IN PHARMA - LEAD TIME AND PRODUCT NOVELTY

- Early phases of customer engagement
- Impact on product design – accelerate time to market
  (Bentch top + data collection on product functionalities)
- Scaling from single product to high volume production – Digital twin for line design
- Accelerate machine design, mechanical
- Lead time reduction on virtual commissioning
- Big data on machine productivity
- Future proof IT upgrades – using virtual machines

DHAVAL PATEL

Director of Manufacturing Science and Technology,
INCOG BioPharma Services

Dhaval Patel is the Director of Manufacturing Science and Technology (MSAT) at INCOG Biopharma, bringing over 17 years of experience in the biopharmaceutical industry. For the past three years, Dhaval has played a critical leadership role at INCOG, where he oversees technical transfer, new product introduction, and the implementation of advanced manufacturing technologies.
Dhaval is known for driving complex solutions that enhance manufacturing efficiency and product quality. He is deeply involved in designing and optimizing innovative processes that support scalability, regulatory compliance, and operational robustness across a range of biologic products.
His approach combines strong technical knowledge with a forward-thinking mindset to solve high-impact challenges in biopharma manufacturing.
Prior to joining INCOG, Dhaval spent 12 years at Cook Pharmica (later Catalent), where he was instrumental in managing large-scale technical transfers and bringing new products into commercial manufacturing. His collaborative style and cross-functional leadership have contributed to the successful launch of numerous biologics, consistently meeting project timelines and quality expectations.

READY-TO-USE PACKAGING BENEFITS & COST SAVINGS

The adoption of Ready-to-Use (RTU) components in manufacturing and pharmaceutical operations presents significant advantages in terms of operational efficiency, cost savings, and quality assurance. RTU solutions streamline production by reducing line changeover times and eliminating the need for time-consuming validation processes. The RTU setup accommodates various container sizes with minimal equipment changes, which in turn reduces training requirements and personnel costs, thereby accelerating time-to-market. Additionally, RTU systems contribute to product integrity by minimizing glass contact during shipping and manufacturing, leading to fewer defects. The widespread availability of standardized components and their compatibility with diverse filling equipment further enhances adaptability and scalability. The presentation will also include a real case study illustrating production flows on a multi-use, multi-container filling line.

PIETRO NEGRI

Partner,
Asset

Pietro is Partner at Asset's Operations and Supply Chain Management Practice. He holds a degree in Management Engineering from the Polytechnic University of Milan. His work centers on the application of quantitative methods—particularly dynamic simulation modeling—to improve supply chain performance and environmental sustainability. Pietro supports companies in redesigning production and logistics networks, optimizing inventory, and in decarbonizing their operations. He is also actively involved in managerial training programs and executive education, collaborating with different Italian faculties.

CLAUDIO VENOSTA

Supply Chain and Operations Consultant,
Asset

Claudio has been a Consultant in Asset's Operations and Supply Chain Management Practice since 2021. He holds a Master's degree in Management Engineering from the Polytechnic University of Milan.
He has contributed to a variety of consulting projects across several industries, including Energy & Utilities, Food & Beverage, Hospitality, Consumer Electronics, Luxury & Fashion, and Pharmaceuticals. His main areas of interest include supply chain process optimization, production and logistics network (re)design, change management, and performance measurement.

INNOVATION AND SUSTAINABILITY: A SUCCESS STORY IN THE STEVANATO GROUP SUPPLY CHAIN

With the support of Asset, Stevanato Group developed an advanced simulation model to compare greenhouse gas emissions from its traditional supply chain with those generated by the new Fishers Hub configuration. A customized digital twin enabled the simultaneous analysis of operational performance—such as service times—and environmental impact, including Scope 3 emissions from supplier and partner logistics. The simulation of multiple scenarios quantified the potential reduction in transport-related emissions, providing measurable evidence of the sustainability benefits.

Stevanato Group

INNOVATION ROADSHOW

September 23, 2025
Boston, MA, U.S.

W Boston Hotel,
100 Stuart Street,
Boston, MA, 02116

September 23, 2025
from 9:00 am
to 6:00 pm

Scan the QR code to learn more and register for the event!

stevanatogroup.com